Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia

British Journal of Cancer

Volumn 106, Issue 2, 2012, Pages 262-268

  Byrd, P J ^a   Srinivasan, V ^a   Last, J I ^a   Smith, A ^a   Biggs, P ^a   Carney, E F ^a   Exley, A ^b   Abson, C ^c   Stewart, G S ^a   Izatt, L ^d   Taylor, A M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b St John's Innovation Centre   (United Kingdom)

^c MAIDSTONE HOSPITAL   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ataxia telangiectasia; ATM; breast cancer; radiosensitivity; radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN;

ADULT; ARTICLE; ATAXIA TELANGIECTASIA; BLOOD CULTURE; BREAST CANCER; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION SICKNESS; RADIOSENSITIVITY; SITE DIRECTED MUTAGENESIS; SKIN FIBROBLAST; T LYMPHOCYTE;

ATAXIA TELANGIECTASIA; BREAST NEOPLASMS; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; TUMOR SUPPRESSOR PROTEINS;

EID: 84856509171     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.534     Document Type: Article

References (27)

1. Athma P, Rappaport R, Swift M (1996) Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92(2): 130-134 (Pubitemid 26427675)
2. Austen B, Barone G, Reiman A, Byrd PJ, Baker C, Starczynski J, Nobbs MC, Murphy RP, Enright H, Chaila E, Quinn J, Stankovic T, Pratt G, Taylor AM (2008) Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients. Br J Haematol 142(6): 925-933
3. Barone G, Groom A, Reiman A, Srinivasan V, Byrd PJ, Taylor AM (2009) Modeling ATM mutant proteins from missense changes confirms retained kinase activity. Hum Mutat 30(8): 1222-1230
4. Bernstein JL, Bernstein L, Thompson WD, Lynch CF, Malone KE, Teitelbaum SL, Olsen JH, Anton-Culver H, Boice JD, Rosenstein BS, Borresen-Dale AL, Gatti RA, Concannon P, Haile RW (2003) ATM variants 7271T4G and IVS10-6T4G among women with unilateral and bilateral breast cancer. Br J Cancer 89(8): 1513-1516 (Pubitemid 37386608)
5. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P (2006) Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T4G and c.1066-6T4G (IVS10-6T4G) from the Breast Cancer Family Registry. Hum Mutat 27(11): 1122-1128 (Pubitemid 44730507)
6. Carrillo F, Schneider SA, Taylor AM, Srinivasan V, Kapoor R, Bhatia KP (2009) Prominent oromandibular dystonia and pharyngeal telangiectasia in atypical ataxia telangiectasia. Cerebellum 8(1): 22-27
7. Easton DF (1994) Cancer risks in A-T heterozygotes. Int J Radiat Biol 66(6 Suppl): S177-S182
8. Fang Z, Kozlov S, McKay MJ, Woods R, Birrell G, Sprung CN, Murrell DF, Wangoo K, Teng L, Kearsley JH, Lavin MF, Graham PH, Clarke RA (2010) Low levels of ATM in breast cancer patients with clinical radiosensitivity. Genome Integr 1(1): 9
9. Geoffroy-Perez B, Janin N, Ossian K, Laug A, Croquette MF, Griscelli C, Debre M, Bressac-de-Paillerets B, Aurias A, Stoppa-Lyonnet D, Andrieu N (2001) Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer 93(2): 288-293 (Pubitemid 32574287)
10. Hiel JA, van Engelen BG, Weemaes CM, Broeks A, Verrips A, ter LH, Vingerhoets HM, van den Heuvel LP, Lammens M, Gabreels FJ, Last JI, Taylor AM (2006) Distal spinal muscular atrophy as a major feature in adult-onset ataxia telangiectasia. Neurology 67(2): 346-349 (Pubitemid 44305433)
11. Inskip HM, Kinlen LJ, Taylor AM, Woods CG, Arlett CF (1999) Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 79(7-8): 1304-1307 (Pubitemid 29087915)
12. Janin N, Andrieu N, Ossian K, Lauge A, Croquette MF, Griscelli C, Debre M, Bressac-de-Paillerets B, Aurias A, Stoppa-Lyonnet D (1999) Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 80(7): 1042-1045 (Pubitemid 29233926)
13. Lavin MF (2008) Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9(10): 759-769
14. Mandigers CM, van de Warrenburg BP, Strobbe LJ, Kluijt I, Molenaar AH, Schinagl DA (2011) Ataxia telangiectasia: the consequences of a delayed diagnosis. Radiother Oncol 99(1): 97-98
15. McConville CM, Stankovic T, Byrd PJ, McGuire GM, Yao QY, Lennox GG, Taylor MR (1996) Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet 59(2): 320-330 (Pubitemid 26266347)
16. Olsen JH, Hahnemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L, Kleinerman R, Kaariainen H, Lonnqvist T, Sankila R, Seersholm N, Tretli S, Yuen J, Boice Jr JD, Tucker M (2001) Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries. J Natl Cancer Inst 93(2): 121-127 (Pubitemid 32111989)
17. Reiman A, Srinivasan V, Barone G, Last JI, Wooton LL, Davies G, Verhagen MM, Willemsen MA, Weemaes CM, Byrd PJ, Izatt L, Easton DF, Thompson DJ, Taylor AMR (2011) Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br J Cancer 105(4): 586-591
18. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38(8): 873-875 (Pubitemid 44141653)
19. Shull ER, Lee Y, Nakane H, Stracker TH, Zhao J, Russell HR, Petrini JH, McKinnon PJ (2009) Differential DNA damage signaling accounts for distinct neural apoptotic responses in ATLD and NBS. Genes Dev 23(2): 171-180
20. Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P, Bedenham T, Bradwell AR, Easton DF, Lennox GG, Haites N, Byrd PJ, Taylor AM (1998) ATM mutations and phenotypes in ataxiatelangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 62(2): 334-345 (Pubitemid 28110776)
21. Stewart GS, Last JI, Stankovic T, Haites N, Kidd AM, Byrd PJ, Taylor AM (2001) Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T-4G mutations, showing a less severe phenotype. J Biol Chem 276(32): 30133-30141
22. Sutton IJ, Last JI, Ritchie SJ, Harrington HJ, Byrd PJ, Taylor AM (2004) Adult-onset ataxia telangiectasia due to ATM 5762ins137 mutation homozygosity. Ann Neurol 55(6): 891-895 (Pubitemid 38702588)
23. Swift M, Morrell D, Massey RB, Chase CL (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl JMed 325(26): 1831-1836
24. Taylor AM, Byrd PJ (2005) Molecular pathology of ataxia telangiectasia. J Clin Pathol 58(10): 1009-1015 (Pubitemid 41416047)
25. Thompson D, Antoniou AC, Jenkins M, Marsh A, Chen X, Wayne T, Tesoriero A, Milne R, Spurdle A, Thorstenson Y, Southey M, Giles GG, Khanna KK, Sambrook J, Oefner P, Goldgar D, Hopper JL, Easton D, Chenevix-Trench G (2005a) Two ATM variants and breast cancer risk. Hum Mutat 25(6): 594-595
26. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF (2005b) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97(11): 813-822 (Pubitemid 40909124)
27. Verhagen MM, Abdo WF, Willemsen MA, Hogervorst FB, Smeets DF, Hiel JA, Brunt ER, van Rijn MA, Majoor KD, Oldenburg RA, Broeks A, Last JI, van't Veer LJ, Tijssen MA, Dubois AM, Kremer HP, Weemaes CM, Taylor AM, van DM (2009) Clinical spectrum of ataxiatelangiectasia in adulthood. Neurology 73(6): 430-437